SK Capital Agrees to Buy Majority Stake in Swixx Biopharma

SK Capital deal values Swixx at more than €1.5 billion ($1.8 billion) according to a statement on Monday.

• HBM Healthcare, Swixx founders and other shareholders including Merieux Equity Partners will sell a majority of their current stake in Swixx to SK Capital, while retaining a significant minority holding: statement
• EARLIER: SK Capital Is Said to Near Deal for Drug Distributor Swixx (1)

To contact the reporters on this story:
Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;
Leonard Kehnscherper in London at Lkehnscherpe@bloomberg.net;
Eyk Henning in Frankfurt at ehenning1@bloomberg.net

To contact the editors responsible for this story:
Ben Scent ...